| pubmed-article:20304866 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20304866 | lifeskim:mentions | umls-concept:C0026844 | lld:lifeskim |
| pubmed-article:20304866 | lifeskim:mentions | umls-concept:C0031727 | lld:lifeskim |
| pubmed-article:20304866 | lifeskim:mentions | umls-concept:C1366765 | lld:lifeskim |
| pubmed-article:20304866 | lifeskim:mentions | umls-concept:C1658578 | lld:lifeskim |
| pubmed-article:20304866 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
| pubmed-article:20304866 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20304866 | pubmed:dateCreated | 2010-5-20 | lld:pubmed |
| pubmed-article:20304866 | pubmed:abstractText | It is well recognized that the proliferation of vascular smooth muscle cells (VSMCs) is a key event in the pathogenesis of various vascular diseases, including atherosclerosis and hypertension. We have previously shown that among extracellular signal-regulated protein kinases (ERKs), the 42- and 44-kDa isoforms (ERK1/2) participate in the cellular mitogenic machinery triggered by several VSMCs activators, including insulin (INS) and thrombin (Thr). However, understanding of the intracellular signal transduction pathways involved is incomplete. This review considers the recent findings in INS and Thr signaling mechanisms that modulate the proliferation of VSMCs with particular emphasis on the ERK1/2 signaling pathway, an important mediator of VSMCs hypertrophy and vascular disease. Moreover, because the ERK1/2 pathway have been acknowledged as an important mediator of VSMCs hypertrophy, ERK1/2 is identified as a key target for novel therapeutic interventions to minimize irreversible tissue damage associated with hypertension and atherosclerosis. | lld:pubmed |
| pubmed-article:20304866 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20304866 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20304866 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20304866 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20304866 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20304866 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20304866 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20304866 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20304866 | pubmed:month | May | lld:pubmed |
| pubmed-article:20304866 | pubmed:issn | 1940-1574 | lld:pubmed |
| pubmed-article:20304866 | pubmed:author | pubmed-author:MarchePierreP | lld:pubmed |
| pubmed-article:20304866 | pubmed:author | pubmed-author:KedeesMamdouh... | lld:pubmed |
| pubmed-article:20304866 | pubmed:author | pubmed-author:MikhailidisDi... | lld:pubmed |
| pubmed-article:20304866 | pubmed:author | pubmed-author:IsenovicEsma... | lld:pubmed |
| pubmed-article:20304866 | pubmed:author | pubmed-author:HaidaraMohame... | lld:pubmed |
| pubmed-article:20304866 | pubmed:author | pubmed-author:TrpkovicAndre... | lld:pubmed |
| pubmed-article:20304866 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20304866 | pubmed:volume | 61 | lld:pubmed |
| pubmed-article:20304866 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20304866 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20304866 | pubmed:pagination | 357-64 | lld:pubmed |
| pubmed-article:20304866 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:20304866 | pubmed:meshHeading | pubmed-meshheading:20304866... | lld:pubmed |
| pubmed-article:20304866 | pubmed:meshHeading | pubmed-meshheading:20304866... | lld:pubmed |
| pubmed-article:20304866 | pubmed:meshHeading | pubmed-meshheading:20304866... | lld:pubmed |
| pubmed-article:20304866 | pubmed:meshHeading | pubmed-meshheading:20304866... | lld:pubmed |
| pubmed-article:20304866 | pubmed:meshHeading | pubmed-meshheading:20304866... | lld:pubmed |
| pubmed-article:20304866 | pubmed:meshHeading | pubmed-meshheading:20304866... | lld:pubmed |
| pubmed-article:20304866 | pubmed:meshHeading | pubmed-meshheading:20304866... | lld:pubmed |
| pubmed-article:20304866 | pubmed:meshHeading | pubmed-meshheading:20304866... | lld:pubmed |
| pubmed-article:20304866 | pubmed:meshHeading | pubmed-meshheading:20304866... | lld:pubmed |
| pubmed-article:20304866 | pubmed:meshHeading | pubmed-meshheading:20304866... | lld:pubmed |
| pubmed-article:20304866 | pubmed:meshHeading | pubmed-meshheading:20304866... | lld:pubmed |
| pubmed-article:20304866 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20304866 | pubmed:articleTitle | Involvement of ERK1/2 kinase in insulin-and thrombin-stimulated vascular smooth muscle cell proliferation. | lld:pubmed |
| pubmed-article:20304866 | pubmed:affiliation | Vinca Institute of Nuclear Sciences, University of Belgrade, Laboratory for Molecular Genetics and Radiobiology, Belgrade, Serbia. isenovic@yahoo.com | lld:pubmed |
| pubmed-article:20304866 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20304866 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:20304866 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
